Glenmark Pharma receives USFDA approval for metformin hydrochloride tablets

Glenmark Pharmaceuticals has received final USFDA for metformin hydrochloride tablets used in the management of type-two diabetes.The drug metformin hydrochloride extended release tablets USP, 500 mg and 1000 mg, the generic version of Glumetza extended release tablets, 500 mg and 1,000 mg, of Salix Pharmaceuticals Inc.

According to market estimates, the sales potential for the drug is around USD 226.7 million.

Company Profile : Glenmark Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.